Trials and Fibrillations with Dr John Mandrola

 
 

Trials and Fibrillations with Dr John Mandrola

  • Mandrola's Top 10 Cardiology Stories of 2021 Obesity drugs had a good year, the SGLT2 inhibitors stalled, and Entresto looks less impressive -- these are some of the takes from John Mandrola, MD, in his annual review of cardiology research.
  • AHA 2021 PCI vs CABG for Left Main CAD: A Never-Ending Debate? Controversies surrounding the EXCEL trial left questions about the data on stents vs bypass surgery in left main CAD. John Mandrola, MD, reviews a new independent meta-analysis presented at the 2021 AHA.
  • AHA 2021 Early Surgery in Asymptomatic AS Should Wait Another trial favoring early surgery in patients with asymptomatic aortic stenosis is still not enough to change practice, argues this cardiologist.
  • AHA 2021 Questions Remain on Tricuspid Repair at Time of Mitral Surgery The Cardiothoracic Surgical Trials Network trial on repair of mild-to-moderate tricuspid regurgitation in patients undergoing mitral valve surgery leaves this cardiologist with more questions than answers.
  • AHA 2021 Mandrola Previews the Virtual AHA 2021 Trials on aortic stenosis, atrial fibrillation, and a pragmatic use of EHRs are among the picks from this year's American Heart Association scientific sessions.
  • The MI–Mortality Mismatch: When Lowering MI Doesn't Extend Life An analysis challenges the notion that cardiovascular therapies that lower myocardial infarction extend survival. John Mandrola, MD, sees lessons for clinicians, patients, and researchers.
  • ESC 2021 Ablate-and-Pace Delivers a Huge Win for Those Sick With AF In terms of clinical practice, the APAF-CRT trial was the standout from ESC for this electrophysiologist.
  • ESC 2021 Lessons on AF Screening From the LOOP Study Screening for AF with an implantable monitor was not associated with lower stroke or systemic embolism overall, but the AF threshold was low and usual care was excellent, notes John Mandrola, MD.
  • ESC 2021 Incremental, Not Monumental, Win for Empagliflozin in HFpEF The modest effects compel clinicians to be selective in the use of this costly drug, but there will be subgroups of patients who may benefit more, says John Mandrola, MD.
  • ESC 2021 Mandrola Previews ESC 2021 A potential breakthrough in HFpEF, loop monitoring, a novel ablation strategy, and the saddest trial are highlighted by John Mandrola, MD, in his preview of the 2021 European Society of Cardiology sessions.
  • HRS 2021 The Three Big Stories From HRS 2021 Presentations on pulsed field ablation and left bundle branch pacing caught the eye of this electrophysiologist. However, being able to meet in person trumped all at the 2021 Heart Rhythm Society meeting.
  • Lessons From the Save of Christian Eriksen's Life The Danish soccer star went from 'being gone' to resuscitated. His widely watched experience teaches many lessons about improving care for sudden cardiac death, a major public health problem.
  • ACC 2021 Renal Denervation for Resistant Hypertension Is Not Back on Track The RADIANCE-HTN-TRIO presentation at the recent American College of Cardiology meeting has this cardiologist asking if mineralocorticoid inhibition might beat an invasive procedure for resistant hypertension.
  • ACC 2021 PARADISE-MI Makes Me Question the Benefits of Sacubitril/Valsartan Sacubitril valsartan (Entresto), deemed 'the Big E' by some clinicians, has fallen short in 2 of 3 clinical trials. The latest, presented at the ACC 2021 scientific session, is PARADISE-MI.
  • ACC 2021 Eight Things to Know About the LAAOS III Trial The trial, showing a benefit for surgical left appendage occlusion in patients with AF undergoing cardiac surgery, should change practice, but there are caveats, notes John Mandrola, MD.
  • Mandrola Previews (Virtual) ACC 2021 Presentations on aspirin dosing, surgical left atrial appendage occlusion, heart failure rehab, and rate vs rhythm control are among the top picks from the virtual ACC 2021, according to John Mandrola, MD.
  • A Tribute to Bernard Lown There are lessons for us all in the life and legacy of the renowned cardiologist and peace activist Bernard Lown, notes John Mandrola, MD.
  • Colchicine Post-MI: Close but No Cigar The inflammatory hypothesis of coronary artery disease has gained traction, but prescribing drugs with anti-inflammatory effects has yet to take off. Could recent data on colchicine change that?
  • Five Reasons Sacubitril/Valsartan Should NOT Be Approved for HFpEF The pricey drug Entresto is approved for heart failure with reduced ejection fraction, but should it also get an indication for HF with preserved ejection fraction? Cardiologist John Mandrola, MD, says no.
  • Mandrola's Top 10 in Cardiology for 2020 While the pandemic dominated the medical news, there were both exciting and concerning developments in the world of cardiology.